Parker Rex A, Huang Qi, Tesfamariam Belay
Division of Metabolic and Cardiovascular Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA.
Atherosclerosis. 2003 Jul;169(1):19-29. doi: 10.1016/s0021-9150(03)00100-x.
HMGCoA reductase inhibitors (statins) can have effects outside the target tissue, liver, including serious side-effects such as rhabdomyolysis as well as beneficial pleiotrophic effects. One such effect is upregulation of endothelial nitric oxide synthase (e-NOS) which generally leads to vasorelaxation. However, changing the balance between localized NO and O(2-) fluxes can also lead to oxidant stress and cellular injury through formation of reactive secondary oxidants such as peroxynitrite. We compared different statins for e-NOS subcellular localization, formation of pro-oxidants, and endothelial-dependent vascular function. Vascular relaxation in aortas of statin-dosed rats was inhibited with simvastatin (sevenfold higher EC50 for acetyl-choline induced relaxation) and atorvastatin (twofold increase) but not pravastatin. Ex vivo oxidation of the fluorescent redox probe dihydrorhodamine-123 (DHR-123) was increased in aortas from simvastatin treated rats, indicating increased reactive nitrogen and oxygen species. Human aortic endothelial cells incubated with simvastatin exhibited up to threefold higher intracellular oxidation of DHR-123 along with a twofold increase in total e-NOS protein. The elevated e-NOS was found in the Golgi/mitochondrial fraction and not in the plasma membrane, and using immunofluorescence greater e-NOS was observed proximal to Golgi and cytoskeletal structures and away from plasma membrane in simvastatin-treated cells. The data suggest that the action of lipophilic statins in endothelium can shift e-NOS localization towards intracellular domains, thereby increasing the encounter with metabolically generated O(2-) to produce peroxynitrite and related oxidants. Thus, under some conditions the direct action of lipophilic HMGCoA reductase inhibitors may unbalance NO and O(2-) fluxes and promote oxidant stress, compromising potentially beneficial vascular effects of e-NOS upregulation and increasing the potential for damage to muscle and other tissues.
3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂(他汀类药物)可在目标组织肝脏之外产生作用,包括横纹肌溶解等严重副作用以及有益的多效性作用。其中一种作用是内皮型一氧化氮合酶(e-NOS)的上调,这通常会导致血管舒张。然而,改变局部一氧化氮(NO)和超氧阴离子(O₂⁻)通量之间的平衡也可能通过形成诸如过氧亚硝酸盐等反应性次级氧化剂而导致氧化应激和细胞损伤。我们比较了不同他汀类药物对e-NOS亚细胞定位、促氧化剂形成以及内皮依赖性血管功能的影响。辛伐他汀(乙酰胆碱诱导舒张的半数有效浓度(EC50)高7倍)和阿托伐他汀(增加2倍)可抑制他汀类药物处理大鼠主动脉的血管舒张,但普伐他汀则无此作用。辛伐他汀处理大鼠的主动脉中,荧光氧化还原探针二氢罗丹明123(DHR-123)的体外氧化增加,表明活性氮和氧物种增加。用辛伐他汀孵育的人主动脉内皮细胞显示DHR-123的细胞内氧化高达3倍,同时总e-NOS蛋白增加2倍。升高的e-NOS存在于高尔基体/线粒体部分,而非质膜中,并且使用免疫荧光法在辛伐他汀处理的细胞中观察到高尔基体和细胞骨架结构附近且远离质膜处有更多的e-NOS。数据表明,亲脂性他汀类药物在内皮中的作用可使e-NOS定位向细胞内区域转移,从而增加与代谢产生的O₂⁻的接触,以产生过氧亚硝酸盐和相关氧化剂。因此,在某些情况下,亲脂性3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂的直接作用可能会使NO和O₂⁻通量失衡并促进氧化应激,损害e-NOS上调可能带来的有益血管作用,并增加肌肉和其他组织受损的可能性。